The VC spending gap

Maybe better days ahead for biotech venture despite falloff in new investments

A new report from PricewaterhouseCoopers and the National Venture Capital Association shows the number of companies receiving first-time venture investments has fallen to lows not seen in nearly two decades.

The data compiled by PwC and NVCA on venture investing do not paint a pretty picture. By their count, only 55 life science companies, including just 22 biotechs, received first-time VC dollars in 1H13 -

Read the full 648 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE